www.proactiveinvestors.com.au

www.proactiveinvestors.com.au
Share

Noxopharm Ltd (ASX:NOX) has geared up to accelerate the development of its front-line anti-cancer drug NOX66, after raising $5.5 million via the placement of shares at $0.33 each. The company has raised the funds from sophisticated and institutional investors to fast-track the clinical development of NOX66, currently undergoing clinical...

Immuron (ASX:IMC) has successfully manufactured trial supplies of its clinical candidate IMM-529, an oral immunotherapeutic targeting the prevention of clostridium difficile Infection (CDI). CDI results from disruption of normal, healthy bacteria in the colon, often as a result of antibiotics. IMM-529 is a biological product which is intended to...

Benitec Biopharma (ASX:BLT) has entered into an agreement with Maryland-based Omnia Biologics to manufacture material for its current first-in-man clinical trial for its TT-034 hepatitis C treatment. This ensures the company has enough clinical material to complete the current trial. The company is also moving to establish its own scalable...